(Q40764254)

23 September 2017

title

ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia (English)

1 reference

23 September 2017

Wang B

1

1 reference

23 September 2017

Hak LJ

2

1 reference

23 September 2017

Relling MV

3

1 reference

23 September 2017

Pui CH

4

1 reference

23 September 2017

Woo MH

5

1 reference

23 September 2017

Storm MC

6

1 reference

23 September 2017

publication date

1 May 2000

1 reference

Journal of Immunological Methods

23 September 2017

published in

1 reference

23 September 2017

volume

239

1 reference

23 September 2017

issue

1-2

1 reference

23 September 2017

page(s)

75-83

1 reference

Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Comparative pharmacokinetic studies of three asparaginase preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Cervicovaginal Overproduction of Specific IgG to Human Immunodeficiency Virus (HIV) Contrasts with Normal or Impaired IgA Local Response in HIV Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Toxicity of E. coli L-asparaginase in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Immunological responses to L-asparaginase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900182-4

10.1016/S0022-1759(00)00182-4

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference